Ampersand Capital-backed Nexelis, a provider of assay development and advanced laboratory testing, agreed to acquire ImmunXperts, a biotechnology company. Financial terms were not disclosed. "ImmunXperts' immunology testing expertise will help Nexelis more broadly serve the needs of our customers. Nexelis will now have an unrivaled ability to efficiently develop immunogenicity assays, qualify and validate them in a regulated environment, and then ultimately perform them utilizing our high-throughput platforms in support of clinical trials," Benoit Bouche, Nexelis President and CEO.